raloxifene 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antiestrogens or estrogen receptor modulators, clomifene and tamoxifen derivatives	2351	84449-90-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: raloxifene keoxifene raloxifene hydrochloride evista raloxifene HCl	A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue. Molecular weight: 473.59 Formula: C28H27NO4S CLOGP: 6.86 LIPINSKI: 1 HAC: 5 HDO: 2 TPSA: 70 ALOGS: -5.97 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

raloxifene
keoxifene
raloxifene hydrochloride
evista
raloxifene HCl

A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Molecular weight: 473.59
Formula: C28H27NO4S
CLOGP: 6.86
LIPINSKI: 1
HAC: 5
HDO: 2
TPSA: 70
ALOGS: -5.97
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
60	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.01 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	21.12 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	2 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	7.50 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	10.80 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.05 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	12.10 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 9, 1997	FDA	LILLY

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Endometrial cancer	252.88	11.75	77	19960	2953	56269077
Breast cancer	224.26	11.75	165	19872	48668	56223362
Deep vein thrombosis	164.55	11.75	168	19869	76809	56195221
Retinal vein thrombosis	141.03	11.75	33	20004	445	56271585
Bone density decreased	139.98	11.75	75	19962	12685	56259345
Pulmonary embolism	130.26	11.75	175	19862	106949	56165081
Fracture	106.22	11.75	71	19966	17947	56254083
Femur fracture	103.07	11.75	96	19941	39199	56232831
Spinal compression fracture	103.02	11.75	62	19975	13072	56258958
Retinal vein occlusion	82.85	11.75	30	20007	1978	56270052
Hip fracture	80.75	11.75	71	19966	26902	56245128
Rheumatoid arthritis	78.16	11.75	20	20017	382584	55889446
Transient ischaemic attack	72.96	11.75	74	19963	33503	56238527
Body height decreased	68.54	11.75	42	19995	9143	56262887
Thoracic vertebral fracture	67.10	11.75	32	20005	4231	56267799
Cerebral infarction	66.89	11.75	59	19978	22446	56249584
Compression fracture	65.10	11.75	35	20002	5954	56266076
Fall	63.94	11.75	274	19763	357236	55914794
Pelvic fracture	62.23	11.75	44	19993	12169	56259861
Breast cancer female	61.83	11.75	44	19993	12294	56259736
Breast cancer in situ	60.82	11.75	22	20015	1446	56270584
Drug ineffective	60.17	11.75	151	19886	918838	55353192
Lumbar vertebral fracture	59.60	11.75	31	20006	4933	56267097
Oestrogen receptor assay positive	57.01	11.75	16	20021	458	56271572
Spinal fracture	56.85	11.75	47	19990	16377	56255653
Cerebrovascular accident	56.20	11.75	115	19922	99155	56172875
Visual acuity reduced	51.20	11.75	49	19988	20677	56251353
Toxicity to various agents	49.27	11.75	10	20027	224554	56047476
Osteonecrosis of jaw	49.13	11.75	60	19977	33298	56238732
Product use issue	48.40	11.75	5	20032	186036	56085994
Infusion related reaction	46.47	11.75	9	20028	208922	56063108
Off label use	45.83	11.75	80	19957	556100	55715930
Low turnover osteopathy	45.19	11.75	24	20013	3984	56268046
Wrist fracture	42.85	11.75	35	20002	11991	56260039
Endometrial cancer stage I	42.66	11.75	11	20026	226	56271804
Muscle spasms	42.31	11.75	126	19911	137245	56134785
Systemic lupus erythematosus	41.68	11.75	7	20030	180071	56091959
Osteonecrosis	41.27	11.75	46	19991	23169	56248861
Postmenopausal haemorrhage	40.56	11.75	18	20019	2018	56270012
Hot flush	40.29	11.75	65	19972	46661	56225369
Synovitis	40.28	11.75	5	20032	161300	56110730
Ovarian cancer	40.21	11.75	26	20011	6212	56265818
Glossodynia	37.41	11.75	5	20032	152453	56119577
Product complaint	37.29	11.75	32	20005	11728	56260302
Treatment failure	36.51	11.75	8	20029	170384	56101646
Retinal vascular thrombosis	36.14	11.75	9	20028	160	56271870
Blindness unilateral	35.41	11.75	23	20014	5537	56266493
Myocardial infarction	35.31	11.75	92	19945	92778	56179252
Drug intolerance	34.89	11.75	26	20011	264792	56007238
Uterine cancer	34.74	11.75	21	20016	4458	56267572
Uterine polyp	32.56	11.75	15	20022	1834	56270196
Cataract	30.93	11.75	61	19976	51186	56220844
Therapeutic product effect decreased	29.00	11.75	12	20025	169440	56102590
Endometrial cancer stage II	28.31	11.75	5	20032	13	56272017
Alopecia	28.14	11.75	38	19999	293420	55978610
Oedema peripheral	28.03	11.75	128	19909	171126	56100904
Stress fracture	27.93	11.75	22	20015	7155	56264875
Multiple fractures	27.49	11.75	22	20015	7319	56264711
Hyperlipidaemia	27.36	11.75	33	20004	18076	56253954
Retinal haemorrhage	26.48	11.75	18	20019	4673	56267357
Intestinal pseudo-obstruction	25.91	11.75	10	20027	787	56271243
Rib fracture	25.89	11.75	34	20003	20275	56251755
Pericarditis	25.72	11.75	4	20033	108919	56163111
Lower respiratory tract infection	25.39	11.75	5	20032	114789	56157241
Therapeutic product effect incomplete	24.79	11.75	4	20033	106027	56166003
Injection site haemorrhage	23.53	11.75	34	20003	22167	56249863
Embolism	23.27	11.75	20	20017	7344	56264686
Intentional product use issue	22.79	11.75	4	20033	99729	56172301
Lumbar spinal stenosis	22.68	11.75	16	20021	4407	56267623
Joint swelling	22.62	11.75	43	19994	289757	55982273
Femoral neck fracture	22.34	11.75	20	20017	7751	56264279
Swelling	22.03	11.75	32	20005	239739	56032291
Breast cancer recurrent	21.50	11.75	15	20022	4060	56267970
Osteoporosis	21.26	11.75	53	19984	51999	56220031
Embolism venous	21.18	11.75	13	20024	2835	56269195
Ischaemic stroke	21.16	11.75	28	20009	16814	56255216
Osteopenia	21.03	11.75	29	20008	18112	56253918
Peripheral swelling	20.91	11.75	32	20005	234694	56037336
Oestrogen receptor assay negative	20.82	11.75	3	20034	0	56272030
Pain	20.60	11.75	145	19892	663039	55608991
Wound	20.46	11.75	12	20025	138792	56133238
Back pain	20.18	11.75	149	19888	237021	56035009
Hepatic enzyme increased	19.88	11.75	19	20018	171365	56100665
Diverticulum	19.79	11.75	22	20015	11044	56260986
Thrombosis	19.70	11.75	56	19981	59371	56212659
Dementia Alzheimer's type	19.68	11.75	9	20028	1082	56270948
Fibrocystic breast disease	19.59	11.75	9	20028	1093	56270937
Intramedullary rod insertion	19.57	11.75	11	20026	2040	56269990
General physical health deterioration	19.55	11.75	19	20018	169991	56102039
Bone pain	19.35	11.75	50	19987	50135	56221895
Uterine leiomyoma	19.24	11.75	19	20018	8323	56263707
Spinal osteoarthritis	19.16	11.75	25	20012	14811	56257219
Endometrial hyperplasia	19.11	11.75	8	20029	778	56271252
Infection	18.11	11.75	27	20010	200179	56071851
Humerus fracture	17.86	11.75	18	20019	8079	56263951
Fractured sacrum	17.80	11.75	10	20027	1853	56270177
Product use in unapproved indication	17.06	11.75	15	20022	140807	56131223
Feeling abnormal	16.98	11.75	93	19944	133509	56138521
Psoriatic arthropathy	16.84	11.75	3	20034	74005	56198025
Colitis ischaemic	16.36	11.75	19	20018	10001	56262029
Breast swelling	16.01	11.75	8	20029	1170	56270860
Blood calcium increased	15.96	11.75	17	20020	8137	56263893
Kyphosis	15.84	11.75	10	20027	2292	56269738
Gastrooesophageal reflux disease	15.72	11.75	65	19972	83192	56188838
Foot fracture	15.69	11.75	28	20009	21781	56250249
Coronary artery disease	15.46	11.75	34	20003	30762	56241268
Colon cancer	15.39	11.75	18	20019	9543	56262487
Bone disorder	15.25	11.75	26	20011	19517	56252513
Thrombotic stroke	15.22	11.75	6	20031	500	56271530
Musculoskeletal stiffness	15.14	11.75	20	20017	155987	56116043
Vision blurred	15.07	11.75	64	19973	82879	56189151
Pleurisy	14.95	11.75	16	20021	7700	56264330
Drug abuse	14.83	11.75	3	20034	67607	56204423
Lung neoplasm malignant	14.72	11.75	24	20013	17372	56254658
Endometrial hypertrophy	14.64	11.75	5	20032	277	56271753
Helicobacter infection	14.59	11.75	4	20033	73264	56198766
Insulinoma	14.58	11.75	4	20033	105	56271925
Intervertebral disc protrusion	14.53	11.75	27	20010	21667	56250363
Jaw disorder	14.45	11.75	13	20024	5070	56266960
Haemorrhage subcutaneous	14.03	11.75	10	20027	2800	56269230
Subacute hepatic failure	14.01	11.75	4	20033	122	56271908
Erythema multiforme	13.76	11.75	17	20020	9537	56262493
Gastrointestinal tract adenoma	13.76	11.75	5	20032	333	56271697
Fracture nonunion	13.66	11.75	9	20028	2218	56269812
Osteomyelitis	13.51	11.75	28	20009	24318	56247712
Glaucoma	13.45	11.75	23	20014	17306	56254724
Atrophic vulvovaginitis	13.43	11.75	8	20029	1653	56270377
Tibia fracture	13.30	11.75	12	20025	4696	56267334
Sarcoma uterus	13.14	11.75	3	20034	36	56271994
Breast calcifications	13.11	11.75	7	20030	1174	56270856
Intentional overdose	13.05	11.75	4	20033	68113	56203917
Ligament sprain	12.79	11.75	18	20019	11457	56260573
Radius fracture	12.66	11.75	10	20027	3265	56268765
Pathological fracture	12.64	11.75	15	20022	8074	56263956
Osteoporotic fracture	12.54	11.75	10	20027	3311	56268719
Intervertebral disc degeneration	12.51	11.75	20	20017	14234	56257796
Visual field defect	12.46	11.75	13	20024	6076	56265954
Blindness	12.43	11.75	23	20014	18398	56253632
Vascular headache	12.40	11.75	3	20034	47	56271983
Aortic aneurysm	12.31	11.75	10	20027	3396	56268634
Altered state of consciousness	12.22	11.75	26	20011	22995	56249035
Abdominal discomfort	12.18	11.75	54	19983	277220	55994810
Benign vulval neoplasm	12.12	11.75	3	20034	52	56271978
Fatigue	12.06	11.75	203	19834	788349	55483681
Marasmus	12.03	11.75	5	20032	477	56271553
Road traffic accident	12.00	11.75	29	20008	27898	56244132
Head injury	11.83	11.75	27	20010	25039	56246991

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Endometrial cancer	158.02	12.73	43	14285	1964	70912152
Bone density decreased	127.96	12.73	57	14271	11417	70902699
Breast cancer	109.83	12.73	74	14254	33475	70880641
Retinal vein thrombosis	106.30	12.73	25	14303	627	70913489
Deep vein thrombosis	100.66	12.73	118	14210	110924	70803192
Spinal compression fracture	97.16	12.73	52	14276	15501	70898615
Thoracic vertebral fracture	80.80	12.73	32	14296	4782	70909334
Femur fracture	78.05	12.73	62	14266	36070	70878046
Pulmonary embolism	75.02	12.73	122	14206	155745	70758371
Oestrogen receptor assay positive	73.88	12.73	16	14312	273	70913843
Body height decreased	69.06	12.73	33	14295	7750	70906366
Fracture	65.28	12.73	44	14284	19900	70894216
Breast cancer female	62.53	12.73	34	14294	10452	70903664
Hip fracture	59.97	12.73	48	14280	28215	70885901
Lumbar vertebral fracture	58.09	12.73	27	14301	5960	70908156
Transient ischaemic attack	55.82	12.73	57	14271	45887	70868229
Retinal vein occlusion	53.30	12.73	21	14307	3095	70911021
Endometrial cancer stage I	52.50	12.73	11	14317	159	70913957
Spinal fracture	51.32	12.73	35	14293	16132	70897984
Pelvic fracture	49.68	12.73	30	14298	11231	70902885
Toxicity to various agents	49.02	12.73	9	14319	382163	70531953
Wrist fracture	48.95	12.73	29	14299	10487	70903629
Compression fracture	48.77	12.73	24	14304	6007	70908109
Fall	44.94	12.73	193	14135	443903	70470213
Breast cancer in situ	42.54	12.73	13	14315	898	70913218
Product complaint	42.47	12.73	28	14300	12203	70901913
Postmenopausal haemorrhage	40.35	12.73	14	14314	1445	70912671
Visual acuity reduced	40.16	12.73	38	14290	27892	70886224
Cerebrovascular accident	39.96	12.73	89	14239	143381	70770735
Off label use	39.20	12.73	56	14272	743004	70171112
Hot flush	37.28	12.73	48	14280	49536	70864580
Muscle spasms	36.82	12.73	90	14238	153956	70760160
Multiple fractures	35.05	12.73	20	14308	6745	70907371
Uterine polyp	33.22	12.73	12	14316	1393	70912723
Endometrial cancer stage II	33.16	12.73	5	14323	7	70914109
Osteonecrosis of jaw	32.90	12.73	41	14287	40961	70873155
Ovarian cancer	32.12	12.73	16	14312	4109	70910007
Injection site haemorrhage	31.60	12.73	32	14296	25495	70888621
Uterine cancer	28.52	12.73	14	14314	3485	70910631
Osteonecrosis	28.07	12.73	32	14296	29128	70884988
Bone pain	26.07	12.73	41	14287	50781	70863335
Drug ineffective	24.75	12.73	102	14226	939650	69974466
Oedema peripheral	24.45	12.73	101	14227	227990	70686126
Completed suicide	23.96	12.73	8	14320	227127	70686989
Rheumatoid arthritis	23.49	12.73	15	14313	291790	70622326
Cerebral infarction	22.48	12.73	35	14293	42974	70871142
Feeling abnormal	22	12.73	71	14257	142248	70771868
Death	21.72	12.73	44	14284	510017	70404099
Product use issue	21.46	12.73	5	14323	179932	70734184
Blindness unilateral	21.25	12.73	15	14313	7298	70906818
Hyperlipidaemia	20.99	12.73	25	14303	23838	70890278
Cataract	20.79	12.73	39	14289	55606	70858510
Infusion related reaction	20.76	12.73	7	14321	197527	70716589
Osteoporosis	20.45	12.73	36	14292	48871	70865245
Low turnover osteopathy	19.86	12.73	9	14319	1873	70912243
Myocardial infarction	19.17	12.73	77	14251	171568	70742548
Ischaemic stroke	18.85	12.73	27	14301	30793	70883323
Blood calcium increased	18.49	12.73	15	14313	8978	70905138
Diverticulum	18.49	12.73	18	14310	13675	70900441
Fractured sacrum	18.36	12.73	8	14320	1518	70912598
Intervertebral disc degeneration	18.26	12.73	18	14310	13882	70900234
Endometrial hyperplasia	18.06	12.73	6	14322	543	70913573
Intestinal pseudo-obstruction	18.03	12.73	9	14319	2321	70911795
Uterine leiomyoma	17.27	12.73	12	14316	5695	70908421
Stress fracture	17.00	12.73	12	14316	5838	70908278
Back pain	16.90	12.73	103	14225	271049	70643067
Injection site erythema	16.76	12.73	42	14286	72882	70841234
Atrophic vulvovaginitis	16.70	12.73	7	14321	1208	70912908
Foot fracture	16.36	12.73	20	14308	19580	70894536
Femoral neck fracture	16.30	12.73	14	14314	9059	70905057
Acute kidney injury	16.18	12.73	46	14282	474578	70439538
Retinal haemorrhage	16.15	12.73	13	14315	7697	70906419
Insulinoma	16.01	12.73	4	14324	130	70913986
General physical health deterioration	15.37	12.73	15	14313	236016	70678100
Treatment failure	15.33	12.73	5	14323	144137	70769979
Drug intolerance	15.10	12.73	14	14314	225673	70688443
Intentional product use issue	15.01	12.73	3	14325	120139	70793977
Endometrial hypertrophy	15.00	12.73	4	14324	169	70913947
Osteomyelitis	14.91	12.73	24	14304	30294	70883822
Bone disorder	14.85	12.73	18	14310	17472	70896644
Synovitis	14.62	12.73	4	14324	129224	70784892
Jaw disorder	14.41	12.73	10	14318	4736	70909380
Dementia Alzheimer's type	14.35	12.73	6	14322	1030	70913086
Tibia fracture	14.10	12.73	10	14318	4900	70909216
Vascular headache	14.09	12.73	3	14325	47	70914069
Erythema multiforme	13.99	12.73	17	14311	16547	70897569
Osteoporotic fracture	13.96	12.73	9	14319	3775	70910341
Neutropenia	13.88	12.73	19	14309	257137	70656979
Benign vulval neoplasm	13.81	12.73	3	14325	52	70914064
Breast cancer recurrent	13.78	12.73	8	14320	2785	70911331
Rib fracture	13.76	12.73	21	14307	25335	70888781
Gastrooesophageal reflux disease	13.74	12.73	45	14283	90794	70823322
Breast swelling	13.74	12.73	6	14322	1145	70912971
Product use in unapproved indication	13.72	12.73	13	14315	207465	70706651
Fibrocystic breast disease	13.69	12.73	5	14323	599	70913517
Therapeutic product effect incomplete	13.03	12.73	4	14324	119878	70794238
Multiple organ dysfunction syndrome	12.97	12.73	3	14325	108512	70805604
Thrombotic stroke	12.85	12.73	5	14323	712	70913404
Colitis ischaemic	12.74	12.73	15	14313	14122	70899994

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G03XC01	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Selective estrogen receptor modulators
FDA MoA	N0000000168	Selective Estrogen Receptor Modulators
CHEBI has role	CHEBI:50646	antiosteoporotic
CHEBI has role	CHEBI:50837	oestrogen antagonist
FDA EPC	N0000175826	Estrogen Agonist/Antagonist
MeSH PA	D050071	Bone Density Conservation Agents
MeSH PA	D004965	Estrogen Antagonists
MeSH PA	D020847	Estrogen Receptor Modulators
MeSH PA	D006727	Hormone Antagonists
MeSH PA	D020845	Selective Estrogen Receptor Modulators

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Postmenopausal osteoporosis	indication	102447009
Prevention of Breast Carcinoma	indication
Prevention of Glucocorticoid-Induced Osteoporosis	off-label use
Lupus anticoagulant disorder	contraindication	19267009
Hypertensive disorder	contraindication	38341003	DOID:10763
Thrombosis of retinal vein	contraindication	46085004
Chronic heart failure	contraindication	48447003
Atrial fibrillation	contraindication	49436004	DOID:0060224
Thrombophlebitis	contraindication	64156001	DOID:3875
Deep venous thrombosis	contraindication	128053003
Impaired renal function disorder	contraindication	197663003
Cerebrovascular accident	contraindication	230690007
Pulmonary thromboembolism	contraindication	233935004
Thrombophilia	contraindication	234467004	DOID:2452
Disease of liver	contraindication	235856003	DOID:409
Transient ischemic attack	contraindication	266257000	DOID:224
Pregnancy, function	contraindication	289908002
Hypertriglyceridemia	contraindication	302870006
Cardiovascular event risk	contraindication	395112001
Breastfeeding (mother)	contraindication	413712001
Disorder of coronary artery	contraindication	414024009
Smokes tobacco daily	contraindication	449868002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.13	acidic
pKa2	8.6	acidic
pKa3	9.15	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Estrogen receptor	Nuclear hormone receptor	P03372	ESR1_HUMAN	ANTAGONIST	IC50	9.40	WOMBAT-PK	IUPHAR
Estrogen receptor beta	Nuclear hormone receptor	Q92731	ESR2_HUMAN	MODULATOR	EC50	8	WOMBAT-PK	CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	6.41	DRUG MATRIX
Adenosine receptor A2a	GPCR	P29274	AA2AR_HUMAN		Ki	5.93	DRUG MATRIX
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.21	DRUG MATRIX
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	7.42	CHEMBL
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Enzyme	Q15125	EBP_HUMAN		Ki	9	WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	5.72	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	6.55	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	6.38	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.16	CHEMBL
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.21	DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.30	WOMBAT-PK
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	5.77	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.28	DRUG MATRIX
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN		IC50	8.54	WOMBAT-PK
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN		Ki	6.52	WOMBAT-PK
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	6.97	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.83	DRUG MATRIX
Nuclear receptor subfamily 1 group I member 2	Nuclear hormone receptor	O75469	NR1I2_HUMAN		EC50	4.93	CHEMBL
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	6.32	DRUG MATRIX
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN		Ki	6.19	DRUG MATRIX
Delta-type opioid receptor	GPCR	P41143	OPRD_HUMAN		Ki	5.63	DRUG MATRIX
Acetylcholinesterase	Enzyme	P22303	ACES_HUMAN		IC50	6.40	DRUG MATRIX
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	5.70	DRUG MATRIX
G-protein coupled estrogen receptor 1	GPCR	Q99527	GPER1_HUMAN		EC50	6.50	WOMBAT-PK
Interleukin-6	Cytokine	P05231	IL6_HUMAN		IC50	8.05	WOMBAT-PK
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	5.44	DRUG MATRIX
Bile acid receptor	Nuclear hormone receptor	Q96RI1	NR1H4_HUMAN		IC50	4.94	CHEMBL
Substance-K receptor	GPCR	P21452	NK2R_HUMAN		Ki	5.88	DRUG MATRIX
Phospholipase D1	Enzyme	Q13393	PLD1_HUMAN		IC50	5.40	CHEMBL
Phospholipase D2	Enzyme	O14939	PLD2_HUMAN		IC50	5.47	CHEMBL
Complement C5	Secreted	P01031	CO5_HUMAN		Kd	6.15	CHEMBL
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN		Ki	6.32	DRUG MATRIX
HLA class I histocompatibility antigen, A-3 alpha chain	Unclassified	P04439	1A03_HUMAN		Kd	4.66	CHEMBL
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	5.71	DRUG MATRIX
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	5.83	DRUG MATRIX
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	6.07	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	6.63	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	5.66	CHEMBL
Estrogen receptor	Transcription factor		ESR1_RAT		Ki	9.43	CHEMBL
Estrogen receptor beta	Transcription factor		ESR2_RAT		Ki	8.56	CHEMBL
C-8 sterol isomerase	Enzyme		ERG2_YEAST		Ki	7.18	CHEMBL
Cruzipain	Enzyme		CYSP_TRYCR		IC50	4.48	CHEMBL
Estrogen receptor	Transcription factor		ESR1_RAT ESR2_RAT		IC50	8.73	CHEMBL

External reference:

ID	Source
4024098	VUID
N0000022103	NUI
D02217	KEGG_DRUG
82640-04-8	SECONDARY_CAS_RN
4021080	VANDF
4024098	VANDF
C0244404	UMLSCUI
CHEBI:8772	CHEBI
RAL	PDB_CHEM_ID
CHEMBL81	ChEMBL_ID
CHEMBL1116	ChEMBL_ID
D020849	MESH_DESCRIPTOR_UI
DB00481	DRUGBANK_ID
2820	IUPHAR_LIGAND_ID
5388	INN_ID
YX9162EO3I	UNII
5035	PUBCHEM_CID
166551	RXNORM
11500	MMSL
5410	MMSL
83711	MMSL
d04261	MMSL
007282	NDDF
007283	NDDF
109029006	SNOMEDCT_US
395856004	SNOMEDCT_US
419530003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Evista	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4184	TABLET	60 mg	ORAL	NDA	33 sections
Evista	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4184	TABLET	60 mg	ORAL	NDA	33 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7290	TABLET, FILM COATED	60 mg	ORAL	ANDA	29 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7290	TABLET, FILM COATED	60 mg	ORAL	ANDA	29 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0440-5295	TABLET, FILM COATED	60 mg	ORAL	ANDA	20 sections
Raloxifene hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6902	TABLET, FILM COATED	60 mg	ORAL	ANDA	30 sections
Raloxifene Hydrochloride	Human Prescription Drug Label	1	16714-213	TABLET, FILM COATED	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	31722-256	TABLET	60 mg	ORAL	ANDA	20 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42291-726	TABLET, FILM COATED	60 mg	ORAL	ANDA	31 sections
Raloxifene Hydrochloride	Human Prescription Drug Label	1	43353-253	TABLET, FILM COATED	60 mg	ORAL	ANDA	29 sections
Raloxifene hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43598-505	TABLET, FILM COATED	60 mg	ORAL	ANDA	30 sections
Raloxifene hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3363	TABLET, FILM COATED	60 mg	ORAL	ANDA	29 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3866	TABLET, FILM COATED	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5458	TABLET	60 mg	ORAL	ANDA	27 sections
Raloxifene hydrochloride	Human Prescription Drug Label	1	50090-6177	TABLET, COATED	60 mg	ORAL	ANDA	28 sections
Raloxifene hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50228-306	TABLET, FILM COATED	60 mg	ORAL	ANDA	30 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50268-694	TABLET, FILM COATED	60 mg	ORAL	ANDA	29 sections
Evista	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4170	TABLET	60 mg	ORAL	NDA	29 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	60687-266	TABLET	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	60687-266	TABLET	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-7708	TABLET	60 mg	ORAL	ANDA	27 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8209	TABLET, FILM COATED	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	65162-057	TABLET, FILM COATED	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	65162-057	TABLET, FILM COATED	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	Human Prescription Drug Label	1	65862-709	TABLET, FILM COATED	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	Human Prescription Drug Label	1	66993-661	TABLET, FILM COATED	60 mg	ORAL	ANDA	29 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	68071-2412	TABLET, FILM COATED	60 mg	ORAL	ANDA	30 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	69097-825	TABLET	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	70518-2994	TABLET, FILM COATED	60 mg	ORAL	ANDA	29 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	70518-3046	TABLET	60 mg	ORAL	ANDA	28 sections